Repligen (RGEN) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.39 per share a year ago.
Repligen (RGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen Corporation (RGEN) Presents at 2026 KeyBanc Capital Markets Healthcare Virtual Forum Transcript
Cinctive Capital Management LP bought a new stake in shares of Repligen Corporation (NASDAQ: RGEN) during the undefined quarter, according to its most recent filing with the SEC. The firm bought 25,420 shares of the biotechnology company's stock, valued at approximately $3,398,000. Other hedge funds and other institutional investors have also recently bought
Shares of Repligen Corporation (NASDAQ: RGEN - Get Free Report) have earned an average rating of "Moderate Buy" from the fourteen brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has
Repligen Corporation (RGEN) Presents at Leerink Global Healthcare Conference 2026 Transcript
RGEN tops Q4 EPS estimates as revenues jump 18% Y/Y, with solid organic growth and stronger margins heading into 2026.
Repligen Corporation (RGEN) Q4 2025 Earnings Call Transcript
Repligen (RGEN) came out with quarterly earnings of $0.49 per share, beating the Zacks Consensus Estimate of $0.44 per share. This compares to earnings of $0.44 per share a year ago.
Repligen Corporation (RGEN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Repligen Corporation (RGEN) Presents at Evercore 8th Annual Healthcare Conference Transcript